indeglitazar (PLX204) / Daiichi Sankyo, Pfizer - LARVOL DELTA

Design, synthesis, and biological evaluation of deuterated indolepropionic acid derivatives as novel long-acting pan PPARα/γ/δ agonists. (PubMed, Bioorg Med Chem) - "Furthermore, I-1 significantly reduced liver steatosis, hepatocellular ballooning, inflammation, and fibrosis in NASH model induced by HFD + CCl, and even exerted better therapeutic effect than that of Indeglitazar. With the above attractive efficacy, deuterated derivative I-1 is considered as a promising treatment for metabolic syndrome."

Journal • Dyslipidemia • Fibrosis • Hepatology • Immunology • Inflammation • Metabolic Disorders • Non-alcoholic Steatohepatitis • PPARA

Quercetin ameliorates hepatic fat accumulation in high-fat diet-induced obese mice via PPARs. (PubMed, Food Funct) - "Furthermore, molecular docking results suggested that quercetin can bind to both PPARα and PPARγ, with an even more potent binding affinity than indeglitazar, a pan-agonist of PPARs. In conclusion, quercetin may regulate gluconeogenesis to ameliorate hepatic fat accumulation via targeting PPARα/γ."

Journal • Preclinical • Immunology • Inflammation • Metabolic Disorders • Obesity • IL6 • PCK1 • PPARA • PPARG • TNFA